Igor Malyshev

Prof. Dr. Igor Malyshev

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov Moscow Russian Federation

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
IMIgor Malyshev
Igor Malyshev
IMIgor Malyshev
Igor Malyshev
Macrophages play a key role in immunity. In this review, we consider the traditional notion of macrophage plasticity, data that do not fit into existing concepts, and a hypothesis for existence of a new switch macrophage phenotype. Depending on the microenvironment, macrophages can reprogram their phenotype toward the proinflammatory M1 phenotype or toward the anti-inflammatory M2 phenotype. Macrophage reprogramming involves well-coordinated changes in activities of signalling and posttranslational mechanisms. Macrophage reprogramming is provided by JNK-, PI3K/Akt-, Notch-, JAK/STAT-, TGF-β-, TLR/NF-κB-, and hypoxia-dependent pathways. Posttranscriptional regulation is based on micro-mRNA. We have hypothesized that, in addition to the M1 and M2 phenotypes, an M3 switch phenotype exists. This switch phenotype responds to proinflammatory stimuli with reprogramming towards the anti-inflammatory M2 phenotype or, contrarily, it responds to anti-inflammatory stimuli with reprogramming towards the proinflammatory M1 phenotype. We have found signs of such a switch phenotype in lung diseases. Understanding the mechanisms of macrophage reprogramming will assist in the selection of new therapeutic targets for correction of impaired immunity.

21 August 1995 in FEBS Letters
Verified
Journal Article
Closed access
IMIgor Malyshev
Igor Malyshev
EME.B. Manukhina
E.B. Manukhina
VMV.D. Mikoyan
V.D. Mikoyan
LKL.N. Kubrina
L.N. Kubrina
AVAnatoly F. Vanin
Anatoly F. Vanin

5 August 1996 in FEBS Letters
Verified
Journal Article
Closed access
PDF file
IMIgor Malyshev
Igor Malyshev
AMAlexander V. Malugin
Alexander V. Malugin
LGLidia Yu. Golubeva
Lidia Yu. Golubeva
TZTatiyana A. Zenina
Tatiyana A. Zenina
EMEugenia B. Manukhina
Eugenia B. Manukhina
AVAnatoly F. Vanin
Anatoly F. Vanin

26 January 2017 in Medical Science Monitor Basic Research
Verified
Journal Article
Open access
PDF file
SKSergey Kalish
Sergey Kalish
SLSvetlana Lyamina
Svetlana Lyamina
EMEugenia Manukhina
Eugenia Manukhina
YMYuri Malyshev
Yuri Malyshev
ARAnastasiya Raetskaya
Anastasiya Raetskaya
IMIgor Malyshev
Igor Malyshev
M1 macrophages target tumor cells. However, many tumors produce anti-inflammatory cytokines, which reprogram the anti-tumor M1 macrophages into the pro-tumor M2 macrophages. We have hypothesized that the problem of pro-tumor macrophage reprogramming could be solved by using a special M3 switch phenotype. The M3 macrophages, in contrast to the M1 macrophages, should respond to anti-inflammatory cytokines by increasing production of pro-inflammatory cytokines to retain its anti-tumor properties. Objectives of the study were to form an M3 switch phenotype in vitro and to evaluate the effect of M3 macrophages on growth of Ehrlich ascites carcinoma (EAC) in vitro and in vivo. Tumor growth was initiated by an intraperitoneal injection of EAC cells into C57BL/6J mice. 1) The M3 switch phenotype can be programed by activation of M1-reprogramming pathways with simultaneous inhibition of the M2 phenotype transcription factors, STAT3, STAT6, and/or SMAD3. 2) M3 macrophages exerted an anti-tumor effect both in vitro and in vivo, which was superior to anti-tumor effects of cisplatin or M1 macrophages. 3) The anti-tumor effect of M3 macrophages was due to their anti-proliferative effect. Development of new biotechnologies for restriction of tumor growth using in vitro reprogrammed M3 macrophages is very promising.

1 April 1999 in Nitric Oxide
Verified
Journal Article
Closed access
IMIgor Malyshev
Igor Malyshev
TZTatiana A. Zenina
Tatiana A. Zenina
LGLidia Yu. Golubeva
Lidia Yu. Golubeva
VSValentina A. Saltykova
Valentina A. Saltykova
EMEugenia B. Manukhina
Eugenia B. Manukhina
AVAnatoly F. Vanin
Anatoly F. Vanin

1 October 1999 in Nitric Oxide
Verified
Journal Article
Closed access
EMEugenia B. Manukhina
Eugenia B. Manukhina
IMIgor Malyshev
Igor Malyshev
BSBoris V. Smirin
Boris V. Smirin
SMSvetlana Yu. Mashina
Svetlana Yu. Mashina
VSValentina A. Saltykova
Valentina A. Saltykova
AVAnatoly F. Vanin
Anatoly F. Vanin